000 05741cam a2200433Mi 4500
001 94920
003 ES-MaUEC
005 20230102112638.0
006 m o d
007 cr |n|||||||||
008 161125s2017 sz ob 001 0 eng d
020 _a3319397664
_q(electronic bk.)
020 _a9783319397665
_q(electronic bk.)
020 _z3319397648
020 _z9783319397641
035 _a(OCoLC)964380928
_z(OCoLC)970754462
_z(OCoLC)971041103
_z(OCoLC)971079002
_z(OCoLC)974649867
_z(OCoLC)980125806
_z(OCoLC)980381360
_z(OCoLC)981105956
_z(OCoLC)987066355
_z(OCoLC)988786913
_z(OCoLC)1005752270
_z(OCoLC)1007055659
_z(OCoLC)1008954885
040 _aYDX
_cYDX
_dN$T
_dIDEBK
_dEBLCP
_dGW5XE
_dOCLCF
_dN$T
_dIDB
_dAZU
_dUAB
_dCOO
_dOCLCQ
_dUPM
_dVT2
_dIOG
_dMERER
_dESU
_dUWW
_dOCLCQ
_dJBG
_dIAD
_dICW
_dICN
_dOTZ
_dOCLCQ
_dU3W
_dES-MaUEC
_bspa
050 4 _aRE551
_b2017 EB
245 0 0 _aCystoid macular edema :
_bmedical and surgical management
_cShlomit Schaal, Henry J. Kaplan, editors.
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2017
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
504 _aIncluye referencias bibliográficas e índice
505 0 _aAcknowledgment; Contents; Contributors; Part I: Pathophysiology and Diagnosis of CME; Chapter 1: Introduction; Chapter 2: Mechanisms of€Macular Edema; Introduction; Mechanisms Leading to€ME; Mechanisms Leading to€Increased Retinal Fluid Entry or "Vasogenic" Mechanisms; Starling Equation; Rupture of€Retinal Barriers; Vascular Abnormalities Associated with€Enhanced Permeability; RPE Dysfunction; Mechanisms Leading to€Reduced Retinal Fluid Exit or "Cytotoxic" Mechanisms: Retinal Müller Glia Dysfunction; Mechanical Tractions; Causes of€Macular Edema; Vasogenic Macular Edema.
505 8 _aAnti-vascular Endothelial Growth Factor Medications Intravitreal Methotrexate; Subcutaneous Interferon Alpha; Antitumor Necrosis Factor Alpha Medications; Choosing the€Right Treatment; References; Chapter 5: Medical Management of€CME Associated with€Diabetes; Introduction; Pathophysiology of€DME; Medical Management of€DME; Systemic Control [10, 11]; Glycemic Control; Blood Pressure Control; Renin-Angiotensin System Inhibition; Lipid-Lowering Agents; Topical Therapy; Nonsteroidal Anti-inflammatory Drugs (NSAIDS); Steroids; Other Topical Agents; Intraocular Therapy; Steroids.
505 8 _aAnti-VEGF Summary; References; Chapter 6: Management of€Macular Edema in€Vitreo-Maculopathies; Introduction; Vitreous Biochemistry and€Structure; Aging and€PVD; Anomalous PVD; Primary Vitreo-Maculopathies (APVD Is the€Primary Cause); Vitreo-Macular Traction (VMT); Macular Holes (MH); Macular Pucker (MP); Comorbid Vitreo-Maculopathies (Vitreous Contributes); Vitreous in€Exudative AMD; Vitreous in€Diabetic Macular Edema (DME); Vitreous in€Macular Edema due€to€Retinal Vein Occlusion (RVO); Therapy; Surgical; Chromodissection.
505 8 _aCME Associated with€Vitreoretinal Interface Abnormalities CME Associated with€Uveitis; Role of€Fundus Autofluorescence Imaging in€CME; En Face C-Scan Imaging in€CME; Further Advances in€Imaging CME; Conclusion; References; Part II: Medical Management of CME; Chapter 4: Medical Management of€CME Associated with€Uveitis; Introduction; Nonsteroidal Anti-inflammatory Medications; Corticosteroids; Topical Corticosteroids; Systemic Corticosteroids; Periocular Corticosteroids; Intravitreal Corticosteroids; Intravitreal Corticosteroid Depot Preparations; Ozurdex; Retisert.
505 8 _aRetinal Vein Occlusion Diabetic Macular Edema (DME); Hypertensive Retinopathy; Inflammatory Macular Edema; Macular Edema and€Choroidal Neovascularization; Cytotoxic Macular Edema; Chemotherapy-Induced Macular Edema; Retinal/Choroidal Ischemia and€Macular Edema; Conclusion; References; Chapter 3: Diagnosis of€Cystoid Macular Edema: Imaging; Introduction; CME Associated with€Diabetes: Diabetic Macular Edema; Imaging the€Choroid in€DME; Fluorescein Angiography in€DME; Pseudophakic Cystoid Macular Edema; CME Associated with€Retinal Vascular Occlusions.
520 3 _aWritten for comprehensive ophthalmologists and vitreoretinal surgeons, this book discusses state-of-the-art medical and surgical management of cystoid macular edema (CME) and explains the current understanding of the pathophysiology of the condition and methods of diagnosis. The management approach is clearly detailed for each potential presentation, including CME occurring in association with uveitis, diabetes mellitus, vitreoretinal interface changes, retinal vascular occlusions, and lens-induced pathology. The guidance takes full account of the continued expansion in medical treatment options due to the development of new drugs and the increased availability of minimally invasive surgical procedures. Additionally, since therapeutic approaches to CME depend on a clear understanding of pathophysiologic mechanisms and the structural changes in the vitreous and neurosensory retina revealed by imaging studies, these aspects are carefully considered as well.
650 7 _aRetina
_xDiseases.
_2fast
_0(OCoLC)fst01096200
_9145006
_0comprobar BNE19913484313
700 1 _aKaplan, Henry J.,
_eeditor literario
700 1 _aSchaal, Shlomit,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-39766-5
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988 _aSpringer_Medicine_2017
998 _b02/2018
_dz
_e-
_zSI
999 _c94920
_d94920
_x1